Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Aptevo Therapeutics Inc. Director's Dealing 2018

Mar 14, 2018

35422_dirs_2018-03-13_20284bba-297b-44c6-9e84-a42c7fb6fa44.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aptevo Therapeutics Inc. (APVO)
CIK: 0001671584
Period of Report: 2018-03-09

Reporting Person: Lamothe Jeffrey G. (SVP, CFO and Treasurer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-03-10 Common Stock M 6747 Acquired 71459 Direct
2018-03-10 Common Stock F 1583 $3.13 Disposed 69876 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-03-09 Employee Stock Options (Right to Buy) $3.13 A 67400 Acquired 2028-03-09 Common Stock (67400) Direct
2018-03-10 Restricted Stock Unit $ M 6747 Disposed Common Stock (6747) Direct

Footnotes

F1: Each RSU converts into the Issuer's common stock on a one-for-one basis.

F2: On March 9, 2018, the reporting person was granted 67,400 stock options vesting in three equal annual installments beginning on the first anniversary of the grant date.

F3: The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 10, 2015. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, each RSU was adjusted and assumed by the Issuer. The RSUs fully vested as of March 10, 2018.